This round of financing, led by a large, Boston-based public investment firm, includes new investors Polaris Partners, Aisling Capital, and Redmile Group, Syros said in a press release. Current investors Flagship Ventures, ARCH Venture Partners, WuXi PharmaTech Corporate Venture Fund, and Alexandria Venture Investments also participated in this round.